Loading…
Presenting Features of Breast Cancer Differ by Molecular Subtype
Background Gene expression profiling of breast cancers identifies distinct molecular subtypes that affect prognosis. Our goal was to determine whether presenting features of tumors differ among molecular subtypes. Methods Subtypes were classified by immunohistochemical surrogates as luminal A (estro...
Saved in:
| Published in: | Annals of surgical oncology 2009-10, Vol.16 (10), p.2705-2710 |
|---|---|
| Main Authors: | , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c436t-68f44391f40b145bf6031e0edfe8ae0bee830ee59933d5d9f8f94b6ae0df0e63 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c436t-68f44391f40b145bf6031e0edfe8ae0bee830ee59933d5d9f8f94b6ae0df0e63 |
| container_end_page | 2710 |
| container_issue | 10 |
| container_start_page | 2705 |
| container_title | Annals of surgical oncology |
| container_volume | 16 |
| creator | Wiechmann, Lisa Sampson, Michelle Stempel, Michelle Jacks, Lindsay M. Patil, Sujata M. King, Tari Morrow, Monica |
| description | Background
Gene expression profiling of breast cancers identifies distinct molecular subtypes that affect prognosis. Our goal was to determine whether presenting features of tumors differ among molecular subtypes.
Methods
Subtypes were classified by immunohistochemical surrogates as luminal A (estrogen receptor [ER] and/or progesterone receptor [PR] positive,
HER-2
−), luminal B (ER and/or PR+,
HER-2
+),
HER-2
(ER and PR−,
HER-2
+), or basal (ER, PR,
HER-2
−). Data were obtained from an established, registered database of patients with invasive breast cancer treated at our institution between January 1998 and June 2007. A total of 6,072 tumors were classifiable into molecular subtypes. The χ
2
test, analysis of variance, and multivariate logistic regression analysis were used to determine associations between subtype and clinicopathologic variables.
Results
The distribution of subtypes was luminal A, 71%; luminal B, 8%;
HER-2
, 6%; and basal, 15%. Marked differences in age, tumor size, extent of lymph node involvement, nuclear grade, multicentric/multifocal disease, lymphovascular invasion (LVI), and extensive intraductal component were observed among subtypes. When compared with luminal A tumors, those overexpressing
HER-2
(luminal B,
HER-2
) were significantly more likely to manifest nodal involvement, multifocal, extensive intraductal component, and LVI (
P
|
| doi_str_mv | 10.1245/s10434-009-0606-2 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_734059785</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>734059785</sourcerecordid><originalsourceid>FETCH-LOGICAL-c436t-68f44391f40b145bf6031e0edfe8ae0bee830ee59933d5d9f8f94b6ae0df0e63</originalsourceid><addsrcrecordid>eNp1kE1LAzEQhoMotlZ_gBdZvHhanXzu5qbWT6go2HvI7k5Ky3a3JruH_ntTtlAQPE2Seead8BBySeGWMiHvAgXBRQqgU1CgUnZExlTGF6FyehzPoPJUMyVH5CyEFQDNOMhTMqJaaq44G5P7L48Bm27ZLJIXtF0fr0nrkkePNnTJ1DYl-uRp6VwsxTb5aGss-9r65Lsvuu0Gz8mJs3XAi32dkPnL83z6ls4-X9-nD7O0FFx1qcqdEFxTJ6CgQhZOAacIWDnMLUKBmHNAlFpzXslKu9xpUajYqhyg4hNyM8RufPvTY-jMehlKrGvbYNsHk3EBUme5jOT1H3LV9r6JfzOMZZwLkdEI0QEqfRuCR2c2frm2fmsomJ1bM7g10a3ZuTUszlztg_tijdVhYi8zAmwAQmw1C_SHzf-n_gIUUYMm</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>227334471</pqid></control><display><type>article</type><title>Presenting Features of Breast Cancer Differ by Molecular Subtype</title><source>Springer Nature</source><creator>Wiechmann, Lisa ; Sampson, Michelle ; Stempel, Michelle ; Jacks, Lindsay M. ; Patil, Sujata M. ; King, Tari ; Morrow, Monica</creator><creatorcontrib>Wiechmann, Lisa ; Sampson, Michelle ; Stempel, Michelle ; Jacks, Lindsay M. ; Patil, Sujata M. ; King, Tari ; Morrow, Monica</creatorcontrib><description>Background
Gene expression profiling of breast cancers identifies distinct molecular subtypes that affect prognosis. Our goal was to determine whether presenting features of tumors differ among molecular subtypes.
Methods
Subtypes were classified by immunohistochemical surrogates as luminal A (estrogen receptor [ER] and/or progesterone receptor [PR] positive,
HER-2
−), luminal B (ER and/or PR+,
HER-2
+),
HER-2
(ER and PR−,
HER-2
+), or basal (ER, PR,
HER-2
−). Data were obtained from an established, registered database of patients with invasive breast cancer treated at our institution between January 1998 and June 2007. A total of 6,072 tumors were classifiable into molecular subtypes. The χ
2
test, analysis of variance, and multivariate logistic regression analysis were used to determine associations between subtype and clinicopathologic variables.
Results
The distribution of subtypes was luminal A, 71%; luminal B, 8%;
HER-2
, 6%; and basal, 15%. Marked differences in age, tumor size, extent of lymph node involvement, nuclear grade, multicentric/multifocal disease, lymphovascular invasion (LVI), and extensive intraductal component were observed among subtypes. When compared with luminal A tumors, those overexpressing
HER-2
(luminal B,
HER-2
) were significantly more likely to manifest nodal involvement, multifocal, extensive intraductal component, and LVI (
P
< 0.0001). On multivariate analysis, after controlling for patient age, tumor size, LVI, and nuclear grade,
HER-2
subtype tumors were 2.0 times more likely to have four or more metastatic lymph nodes (
P
< 0.0001) and 1.6 times more likely to have multifocal disease (
P
< 0.0001) compared with patients with luminal A.
Conclusions
Tumor presentation varies among molecular subtypes; this information may be useful in selecting local therapy. Neoadjuvant therapy and lymph nodes evaluation before surgery or neoadjuvant therapy are likely to be beneficial in
HER-2
-overexpressing tumors.</description><identifier>ISSN: 1068-9265</identifier><identifier>EISSN: 1534-4681</identifier><identifier>DOI: 10.1245/s10434-009-0606-2</identifier><identifier>PMID: 19593632</identifier><language>eng</language><publisher>New York: Springer-Verlag</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Breast cancer ; Breast Neoplasms - diagnosis ; Breast Neoplasms - metabolism ; Breast Oncology ; Female ; Humans ; Lymph Nodes - pathology ; Lymphatic Metastasis ; Medicine ; Medicine & Public Health ; Middle Aged ; Neoplasm Invasiveness ; Neoplasm Staging ; Neoplasms, Basal Cell - diagnosis ; Neoplasms, Basal Cell - metabolism ; Oncology ; Prognosis ; Receptor, ErbB-2 - metabolism ; Receptors, Estrogen - metabolism ; Receptors, Progesterone - metabolism ; Surgery ; Surgical Oncology ; Young Adult</subject><ispartof>Annals of surgical oncology, 2009-10, Vol.16 (10), p.2705-2710</ispartof><rights>Society of Surgical Oncology 2009</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c436t-68f44391f40b145bf6031e0edfe8ae0bee830ee59933d5d9f8f94b6ae0df0e63</citedby><cites>FETCH-LOGICAL-c436t-68f44391f40b145bf6031e0edfe8ae0bee830ee59933d5d9f8f94b6ae0df0e63</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19593632$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wiechmann, Lisa</creatorcontrib><creatorcontrib>Sampson, Michelle</creatorcontrib><creatorcontrib>Stempel, Michelle</creatorcontrib><creatorcontrib>Jacks, Lindsay M.</creatorcontrib><creatorcontrib>Patil, Sujata M.</creatorcontrib><creatorcontrib>King, Tari</creatorcontrib><creatorcontrib>Morrow, Monica</creatorcontrib><title>Presenting Features of Breast Cancer Differ by Molecular Subtype</title><title>Annals of surgical oncology</title><addtitle>Ann Surg Oncol</addtitle><addtitle>Ann Surg Oncol</addtitle><description>Background
Gene expression profiling of breast cancers identifies distinct molecular subtypes that affect prognosis. Our goal was to determine whether presenting features of tumors differ among molecular subtypes.
Methods
Subtypes were classified by immunohistochemical surrogates as luminal A (estrogen receptor [ER] and/or progesterone receptor [PR] positive,
HER-2
−), luminal B (ER and/or PR+,
HER-2
+),
HER-2
(ER and PR−,
HER-2
+), or basal (ER, PR,
HER-2
−). Data were obtained from an established, registered database of patients with invasive breast cancer treated at our institution between January 1998 and June 2007. A total of 6,072 tumors were classifiable into molecular subtypes. The χ
2
test, analysis of variance, and multivariate logistic regression analysis were used to determine associations between subtype and clinicopathologic variables.
Results
The distribution of subtypes was luminal A, 71%; luminal B, 8%;
HER-2
, 6%; and basal, 15%. Marked differences in age, tumor size, extent of lymph node involvement, nuclear grade, multicentric/multifocal disease, lymphovascular invasion (LVI), and extensive intraductal component were observed among subtypes. When compared with luminal A tumors, those overexpressing
HER-2
(luminal B,
HER-2
) were significantly more likely to manifest nodal involvement, multifocal, extensive intraductal component, and LVI (
P
< 0.0001). On multivariate analysis, after controlling for patient age, tumor size, LVI, and nuclear grade,
HER-2
subtype tumors were 2.0 times more likely to have four or more metastatic lymph nodes (
P
< 0.0001) and 1.6 times more likely to have multifocal disease (
P
< 0.0001) compared with patients with luminal A.
Conclusions
Tumor presentation varies among molecular subtypes; this information may be useful in selecting local therapy. Neoadjuvant therapy and lymph nodes evaluation before surgery or neoadjuvant therapy are likely to be beneficial in
HER-2
-overexpressing tumors.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Breast cancer</subject><subject>Breast Neoplasms - diagnosis</subject><subject>Breast Neoplasms - metabolism</subject><subject>Breast Oncology</subject><subject>Female</subject><subject>Humans</subject><subject>Lymph Nodes - pathology</subject><subject>Lymphatic Metastasis</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Neoplasm Invasiveness</subject><subject>Neoplasm Staging</subject><subject>Neoplasms, Basal Cell - diagnosis</subject><subject>Neoplasms, Basal Cell - metabolism</subject><subject>Oncology</subject><subject>Prognosis</subject><subject>Receptor, ErbB-2 - metabolism</subject><subject>Receptors, Estrogen - metabolism</subject><subject>Receptors, Progesterone - metabolism</subject><subject>Surgery</subject><subject>Surgical Oncology</subject><subject>Young Adult</subject><issn>1068-9265</issn><issn>1534-4681</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><recordid>eNp1kE1LAzEQhoMotlZ_gBdZvHhanXzu5qbWT6go2HvI7k5Ky3a3JruH_ntTtlAQPE2Seead8BBySeGWMiHvAgXBRQqgU1CgUnZExlTGF6FyehzPoPJUMyVH5CyEFQDNOMhTMqJaaq44G5P7L48Bm27ZLJIXtF0fr0nrkkePNnTJ1DYl-uRp6VwsxTb5aGss-9r65Lsvuu0Gz8mJs3XAi32dkPnL83z6ls4-X9-nD7O0FFx1qcqdEFxTJ6CgQhZOAacIWDnMLUKBmHNAlFpzXslKu9xpUajYqhyg4hNyM8RufPvTY-jMehlKrGvbYNsHk3EBUme5jOT1H3LV9r6JfzOMZZwLkdEI0QEqfRuCR2c2frm2fmsomJ1bM7g10a3ZuTUszlztg_tijdVhYi8zAmwAQmw1C_SHzf-n_gIUUYMm</recordid><startdate>20091001</startdate><enddate>20091001</enddate><creator>Wiechmann, Lisa</creator><creator>Sampson, Michelle</creator><creator>Stempel, Michelle</creator><creator>Jacks, Lindsay M.</creator><creator>Patil, Sujata M.</creator><creator>King, Tari</creator><creator>Morrow, Monica</creator><general>Springer-Verlag</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope></search><sort><creationdate>20091001</creationdate><title>Presenting Features of Breast Cancer Differ by Molecular Subtype</title><author>Wiechmann, Lisa ; Sampson, Michelle ; Stempel, Michelle ; Jacks, Lindsay M. ; Patil, Sujata M. ; King, Tari ; Morrow, Monica</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c436t-68f44391f40b145bf6031e0edfe8ae0bee830ee59933d5d9f8f94b6ae0df0e63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Breast cancer</topic><topic>Breast Neoplasms - diagnosis</topic><topic>Breast Neoplasms - metabolism</topic><topic>Breast Oncology</topic><topic>Female</topic><topic>Humans</topic><topic>Lymph Nodes - pathology</topic><topic>Lymphatic Metastasis</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Neoplasm Invasiveness</topic><topic>Neoplasm Staging</topic><topic>Neoplasms, Basal Cell - diagnosis</topic><topic>Neoplasms, Basal Cell - metabolism</topic><topic>Oncology</topic><topic>Prognosis</topic><topic>Receptor, ErbB-2 - metabolism</topic><topic>Receptors, Estrogen - metabolism</topic><topic>Receptors, Progesterone - metabolism</topic><topic>Surgery</topic><topic>Surgical Oncology</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wiechmann, Lisa</creatorcontrib><creatorcontrib>Sampson, Michelle</creatorcontrib><creatorcontrib>Stempel, Michelle</creatorcontrib><creatorcontrib>Jacks, Lindsay M.</creatorcontrib><creatorcontrib>Patil, Sujata M.</creatorcontrib><creatorcontrib>King, Tari</creatorcontrib><creatorcontrib>Morrow, Monica</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>ProQuest_Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><jtitle>Annals of surgical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wiechmann, Lisa</au><au>Sampson, Michelle</au><au>Stempel, Michelle</au><au>Jacks, Lindsay M.</au><au>Patil, Sujata M.</au><au>King, Tari</au><au>Morrow, Monica</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Presenting Features of Breast Cancer Differ by Molecular Subtype</atitle><jtitle>Annals of surgical oncology</jtitle><stitle>Ann Surg Oncol</stitle><addtitle>Ann Surg Oncol</addtitle><date>2009-10-01</date><risdate>2009</risdate><volume>16</volume><issue>10</issue><spage>2705</spage><epage>2710</epage><pages>2705-2710</pages><issn>1068-9265</issn><eissn>1534-4681</eissn><abstract>Background
Gene expression profiling of breast cancers identifies distinct molecular subtypes that affect prognosis. Our goal was to determine whether presenting features of tumors differ among molecular subtypes.
Methods
Subtypes were classified by immunohistochemical surrogates as luminal A (estrogen receptor [ER] and/or progesterone receptor [PR] positive,
HER-2
−), luminal B (ER and/or PR+,
HER-2
+),
HER-2
(ER and PR−,
HER-2
+), or basal (ER, PR,
HER-2
−). Data were obtained from an established, registered database of patients with invasive breast cancer treated at our institution between January 1998 and June 2007. A total of 6,072 tumors were classifiable into molecular subtypes. The χ
2
test, analysis of variance, and multivariate logistic regression analysis were used to determine associations between subtype and clinicopathologic variables.
Results
The distribution of subtypes was luminal A, 71%; luminal B, 8%;
HER-2
, 6%; and basal, 15%. Marked differences in age, tumor size, extent of lymph node involvement, nuclear grade, multicentric/multifocal disease, lymphovascular invasion (LVI), and extensive intraductal component were observed among subtypes. When compared with luminal A tumors, those overexpressing
HER-2
(luminal B,
HER-2
) were significantly more likely to manifest nodal involvement, multifocal, extensive intraductal component, and LVI (
P
< 0.0001). On multivariate analysis, after controlling for patient age, tumor size, LVI, and nuclear grade,
HER-2
subtype tumors were 2.0 times more likely to have four or more metastatic lymph nodes (
P
< 0.0001) and 1.6 times more likely to have multifocal disease (
P
< 0.0001) compared with patients with luminal A.
Conclusions
Tumor presentation varies among molecular subtypes; this information may be useful in selecting local therapy. Neoadjuvant therapy and lymph nodes evaluation before surgery or neoadjuvant therapy are likely to be beneficial in
HER-2
-overexpressing tumors.</abstract><cop>New York</cop><pub>Springer-Verlag</pub><pmid>19593632</pmid><doi>10.1245/s10434-009-0606-2</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1068-9265 |
| ispartof | Annals of surgical oncology, 2009-10, Vol.16 (10), p.2705-2710 |
| issn | 1068-9265 1534-4681 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_734059785 |
| source | Springer Nature |
| subjects | Adult Aged Aged, 80 and over Breast cancer Breast Neoplasms - diagnosis Breast Neoplasms - metabolism Breast Oncology Female Humans Lymph Nodes - pathology Lymphatic Metastasis Medicine Medicine & Public Health Middle Aged Neoplasm Invasiveness Neoplasm Staging Neoplasms, Basal Cell - diagnosis Neoplasms, Basal Cell - metabolism Oncology Prognosis Receptor, ErbB-2 - metabolism Receptors, Estrogen - metabolism Receptors, Progesterone - metabolism Surgery Surgical Oncology Young Adult |
| title | Presenting Features of Breast Cancer Differ by Molecular Subtype |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T10%3A32%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Presenting%20Features%20of%20Breast%20Cancer%20Differ%20by%20Molecular%20Subtype&rft.jtitle=Annals%20of%20surgical%20oncology&rft.au=Wiechmann,%20Lisa&rft.date=2009-10-01&rft.volume=16&rft.issue=10&rft.spage=2705&rft.epage=2710&rft.pages=2705-2710&rft.issn=1068-9265&rft.eissn=1534-4681&rft_id=info:doi/10.1245/s10434-009-0606-2&rft_dat=%3Cproquest_cross%3E734059785%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c436t-68f44391f40b145bf6031e0edfe8ae0bee830ee59933d5d9f8f94b6ae0df0e63%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=227334471&rft_id=info:pmid/19593632&rfr_iscdi=true |